Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past several shares. My 1st CytoDyn post, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview that I came away with a poor opinion of the business.

Irony of irony, the bad opinion of mine of the business has grown steadily, although the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this technology as well as connected intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) as well as the very first brand new drug program approval ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it has this individual therapy in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple presentations and multiple publications.

Might it all be smoke and mirrors? That’s a question I have been asking myself from the really start of the interest of mine in this particular organization. Judging by way of the multiples of thousands of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or even some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *